3SBio completes HKD4.17bn IPO on the HKEX
Executive Summary
Chinese biotech 3SBio Inc. netted HKD4.17bn ($538mm) in a global initial public offering on the HKEX through the sale of 484.9mm shares at HKD9.10, the high end of its anticipated range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice